1. The addition of deep hyperthermia to gemcitabine-based chemoradiation may achieve enhanced survival in unresectable locally advanced adenocarcinoma of the pancreas
- Author
-
Bernhard C. Pestalozzi, Alexander Siebenhüner, Oliver Riesterer, Stephan Bodis, Christoph Mamot, Dietmar Marder, Niloy R. Datta, Emsad Puric, O. Timm, J. Knuchel, S. Khan, Matthias Guckenberger, S. Rogers, University of Zurich, and Rogers, S J
- Subjects
Oncology ,Hyperthermia ,medicine.medical_specialty ,Locally advanced pancreatic cancer ,medicine.medical_treatment ,R895-920 ,610 Medicine & health ,urologic and male genital diseases ,Article ,030218 nuclear medicine & medical imaging ,Medical physics. Medical radiology. Nuclear medicine ,03 medical and health sciences ,0302 clinical medicine ,HEATPAC ,Internal medicine ,medicine ,2741 Radiology, Nuclear Medicine and Imaging ,Radiology, Nuclear Medicine and imaging ,RC254-282 ,Chemotherapy ,Radiotherapy ,business.industry ,Sensitisation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,10044 Clinic for Radiation Oncology ,Gemcitabine ,Radiation therapy ,medicine.anatomical_structure ,Chemoradiation ,030220 oncology & carcinogenesis ,Concomitant ,10032 Clinic for Oncology and Hematology ,Adenocarcinoma ,2730 Oncology ,Pancreas ,business ,medicine.drug - Abstract
Highlights • Intensification of chemoradiation with hyperthermia was feasible in nine patients with LAPC. • Only one grade three toxicity was reported and two tumours became resectable. • The 24 months median OS and 100% 1 year OS are superior to historical series., Introduction Driven by the current unsatisfactory outcomes for patients with locally advanced pancreatic cancer (LAPC), a biologically intensified clinical protocol was developed to explore the feasibility and efficacy of FOLFORINOX chemotherapy followed by deep hyperthermia concomitant with chemoradiation and subsequent FOLFORINOX chemotherapy in patients with LAPC. Methods Nine patients with LAPC were treated according to the HEATPAC Phase II trial protocol which consists of 4 cycles of FOLFORINOX chemotherapy followed by gemcitabine-based chemoradiation to 56 Gy combined with weekly deep hyperthermia and then a further 8 cycles of FOLFORINOX chemotherapy. Results One grade three related toxicity was reported and two tumours became resectable. The median overall survival was 24 months and 1 year overall survival was 100%. Conclusions Intensification of chemoradiation with deep hyperthermia was feasible in nine consecutive patients with LAPC.
- Published
- 2021